MONOPAR THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6289 USD | +1.44% |
|
+3.10% | +84.86% |
| May. 24 | Monopar Therapeutics Names Karthik Radhakrishnan as CFO | MT |
| May. 24 | Monopar Therapeutics Inc. Announces CFO Changes | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.98M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-2
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.44% | ||
| 1 week | +3.10% | ||
| Current month | -4.73% | ||
| 1 month | -4.28% | ||
| 3 months | -51.62% | ||
| 6 months | +104.19% | ||
| Current year | +84.86% |
1 week
0.59
0.65
1 month
0.570.82
Current year
0.311.73
1 year
0.271.75
3 years
0.276.98
5 years
0.2748.00
10 years
0.2748.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 40 | 14-11-30 | |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
Laura Kelly
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brown
BRD | Director/Board Member | 67 | 14-11-30 |
Arthur Klausner
BRD | Director/Board Member | 64 | 17-07-31 |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.6289 | +1.44% | 58,774 |
| 24-05-23 | 0.62 | +0.88% | 36,124 |
| 24-05-22 | 0.6146 | +0.57% | 50,092 |
| 24-05-21 | 0.6111 | -1.42% | 38,357 |
| 24-05-20 | 0.6199 | +1.62% | 57,746 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6289
USD
Average target price
2.08
USD
Spread / Average Target
+230.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +84.86% | 10.98M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- MNPR Stock
